ATHA Stock Recent News
ATHA LATEST HEADLINES
Its mid-stage clinical trial failed to help patients with Alzheimer's.
Athira Pharma (ATHA) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton. The post Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results appeared first on InvestorPlace.
Athira Pharma Inc (NASDAQ: ATHA) shares are falling to 52-week lows after announcing disappointing topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer's disease (AD). The study did not meet the primary endpoint.
Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease. Athira said the primary endpoint of change in biomarker.